Fedorova N S, Abrosimov A Yu, Dzeranova L K, Pigarova E A, Dedov I I
National Medical Research Center of Endocrinology, Ministry of Health of Russia, Moscow, Russia.
Arkh Patol. 2018;80(3):34-39. doi: 10.17116/patol201880334-39.
To present the histological and immunohistochemical characteristics of pituitary lactotroph adenomas (PLAs) resistant to dopamine agonist treatment.
The investigators examined paraffin-embedded blocks and histological sections obtained from 19 patients (13 women, 6 men), whose median age was 29 (19, 38) years, after surgical treatment (adenomectomy) for PLAs resistant to dopamine agonist treatment. Immunohistological examination was performed using antibodies against prolactin (PRL), growth hormone (GH), thyroid-stimulating hormone (TSH), adrenocorticotropic hormone (ACTH), luteinizing hormone (LH), follicle-stimulating hormone (FSH), type 2 dopamine receptors (DR), estrogen receptors-α (ERα), the proliferation marker Ki-67, and the endothelial cell marker CD34.
The expression of PRL by adenoma cells was revealed in all the patients. The coexpression of PRL and GH without clinical and laboratory signs of acromegaly was established in 3 cases. No expression of TSH, ACTH, LH, or FSH was revealed in any cases. Positive immunoreaction using antibodies against DR and ERα was detected in 8 and 6 cases, respectively. No expression of any of the studied receptors was found in 6 patients. Ki-67 was more than 3% in 3 patients and higher in patients with supra- or retrosellar growth. There was a positive correlation between the serum level of Ki-67 and that of PRL at the onset of the disease. There were 37 (25, 85) adenoma vessels, as measured by CD34 immunoexpression. It was ascertained that the patients with parasellar adenoma had more tumor vessels than those without parasellar growth of adenoma and that with the latter invading the cavernous vessels, the number of vessels was statistically significantly more.
PLAs resistant to dopamine agonists in addition to PRL (100%) can express GH in 16% of cases are characterized by the immunoexpression of DR (42%) and ERα (32%), a low proliferative activity, increased angiogenesis in the adenomas with parasellar growth and invasion into the cavernous sinus.
呈现对多巴胺激动剂治疗耐药的垂体催乳素腺瘤(PLAs)的组织学和免疫组化特征。
研究者检查了19例患者(13名女性,6名男性)手术治疗(腺瘤切除术)后获得的石蜡包埋块和组织切片,这些患者为对多巴胺激动剂治疗耐药的PLAs,中位年龄为29(19,38)岁。使用抗催乳素(PRL)、生长激素(GH)、促甲状腺激素(TSH)、促肾上腺皮质激素(ACTH)、黄体生成素(LH)、卵泡刺激素(FSH)、2型多巴胺受体(DR)、雌激素受体-α(ERα)、增殖标志物Ki-67和内皮细胞标志物CD34的抗体进行免疫组织学检查。
所有患者的腺瘤细胞均显示PRL表达。3例患者中发现PRL和GH共表达,但无肢端肥大症的临床和实验室体征。所有病例均未发现TSH、ACTH、LH或FSH表达。分别在8例和6例中检测到使用抗DR和ERα抗体的阳性免疫反应。6例患者未发现任何研究受体的表达。3例患者的Ki-67超过3%,鞍上或鞍后生长的患者中Ki-67更高。疾病发作时血清Ki-67水平与PRL水平呈正相关。通过CD34免疫表达测量,有37(25,85)条腺瘤血管。确定鞍旁腺瘤患者的肿瘤血管比无鞍旁生长的腺瘤患者更多,且当后者侵犯海绵窦时血管数量在统计学上显著更多。
对多巴胺激动剂耐药的PLAs除PRL(100%)外,16%的病例可表达GH,其特征为DR(42%)和ERα(32%)的免疫表达、低增殖活性、鞍旁生长并侵犯海绵窦的腺瘤中血管生成增加。